Oxford BioMedica Shares Gain on Insider Purchase and Stable Earnings Outlook

Oxford BioMedica (LSE:OXB) shares gained 2.4% to 516p in Wednesday trading, continuing a recovery from multi-year lows seen earlier in September. The move was supported by a recent signal of insider confidence and a stable financial outlook provided in the company's first-half results.

Insider Buying Signals Confidence

A key catalyst for the stock's performance was a regulatory disclosure filed on September 28, 2026, revealing an open-market share purchase by Peter Soelkner, the company's Non-Executive Director and Vice Chair. While the size of the transaction was not specified as large, such purchases by board members are often interpreted by investors as a strong vote of confidence in a company's future prospects.

H1 Results and Outlook

The positive sentiment follows the company's interim results for the first half of 2026, which were released on September 22. Key takeaways from the report include:

Ad

• H1 Revenue: £80.2 million
• Revenue Backlog: Approximately £193 million
• Full-Year Guidance: Maintained for 2026

Analysts at Panmure Liberum noted that the results were in line with the company's revised guidance issued in August, suggesting a stabilization of its financial performance. The substantial revenue backlog provides a degree of visibility into future earnings.

Market Context

A constructive broader market environment, with the mid-cap FTSE 250 index also trading higher, provided an additional tailwind for the stock. While Oxford BioMedica's shares have extended their recovery from a 52-week low of 420p, they remain significantly below the 52-week peak of 950p, indicating a long path to a full recovery.